Evidence map›Paper›PMID 35174653›Full record

ArticleESC heart failure2022

Cardiac allograft vasculopathy and donor age affecting permanent pacemaker implantation after heart transplantation.

Stefan Roest, Olivier C Manintveld, Marit A E Kolff, Ferdi Akca, Jesse F Veenis, Alina A Constantinescu, Jasper J Brugts, Ozcan Birim, Lennie M van Osch-Gevers, Tamas Szili-Torok and 1 more

Open access · goldAbstract read
In one paragraph

Article in ESC heart failure, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Stefan RoestDepartment of Cardiology, Thorax Center, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands.
Olivier C ManintveldDepartment of Cardiology, Thorax Center, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands.
Marit A E KolffDepartment of Cardiology, Thorax Center, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands.
Ferdi AkcaDepartment of Cardiothoracic Surgery, Thorax Center, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands.
Jesse F VeenisDepartment of Cardiology, Thorax Center, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands.
Alina A ConstantinescuDepartment of Cardiology, Thorax Center, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands.
Jasper J BrugtsDepartment of Cardiology, Thorax Center, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands.
Ozcan BirimErasmus MC Transplant Institute, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands.
Lennie M van Osch-GeversErasmus MC Transplant Institute, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands.
Tamas Szili-TorokDepartment of Cardiology, Thorax Center, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands.
Kadir CaliskanDepartment of Cardiology, Thorax Center, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands.
Erasmus University Rotterdam · NLErasmus MC · NLErasmus MC Cancer Institute · NLErasmus MC Transplant Institute

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsThe need for permanent pacemakers (PMs) after heart transplantation (HT) is increasing. The aim was to determine the influence of cardiac allograft vasculopathy (CAV), donor age, and other risk factors on PM implantations early and late after HT and its effect on survival. METHODS AND

resultsA retrospective, single-centre study was performed including HTs from 1984 to July 2018. Early PM was defined as PM implantation ≤90 days and late PM as PM > 90 days. Risk factors for PM and survival after PM were determined with (time-dependent) multivariable Cox regression. Out of 720 HTs performed, 62 were excluded (55 mortalities ≤30 days and 7 retransplantations). Of the remaining 658 patients, 95 (14%) needed a PM: 38 (6%) early and 57 (9%) late during follow-up (median 9.3 years). Early PM risk factors were donor age [hazard ratio (HR) 1.06, P < 0.001], ischaemic time (HR 1.01, P < 0.001), and in adults amiodarone use before HT (HR 2.02, P = 0.045). Late PM risk factors were donor age (HR 1.03, P = 0.024) and CAV (HR 3.59, P < 0.001). Late PM compromised survival (HR 2.05, P < 0.001), while early PM did not (HR 0.77, P = 0.41).

conclusionsRisk factors for early PM implantation were donor age, ischaemic time, and in adults amiodarone use before HT. Late PM implantation risk factors were donor age and CAV. Late PM diminished survival, which is probably a surrogate marker for underlying progressive cardiac disease.

Indexed as

Heart DiseasesHeart TransplantationPacemaker, ArtificialAdultAllograftsHumansRetrospective StudiesCardiac allograft vasculopathyDonor ageHeart transplantationPacemaker implantationRisk factors

Identifiers

PMID35174653
PMCPMC8934965
OpenAlexW4213200065

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.